Radical reforms to China’s IP system are set to benefit pharma and biotech patentees, but several key questions remain unanswered
Reset password
Register to access two of our subscriber only articles per month.
Register
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.
Subscribe
Author | Life sciences reporter
[email protected]
@IAM_Alerts In a major intervention, former @uspto head Andrei Iancu has issued a stinging critique of the Biden Administration… https://t.co/z7mu24Nfuy Read more
@IAM_Alerts Korea's top auto supplier has pledged to bolster its patent portfolio amidst growing litigation in the sector and g… https://t.co/ECJFlISva6 Read more
@IAM_Alerts RT @IAM_Alerts: The IAM Sunday Supplement has been published, this week it includes: Brazil kills-off thousands of pharma IP rights; Oppo a… Read more
@IAM_Alerts The IAM Sunday Supplement has been published, this week it includes: Brazil kills-off thousands of pharma IP rights… https://t.co/NWn2Ax33f1 Read more
